Tolerability of clindamycin/tretinoin gel vs. tretinoin microsphere gel and adapalene gel

Journal of Drugs in Dermatology

Volumn 8, Issue 4, 2009, Pages 383-388

  Leyden, James ^a   Wortzman, Mitchell ^b   Baldwin, Edward K ^c  

^a Skin Study Center   (United States)

^b Medicis   (United States)

^c Julie and Edward Baldwin Partners   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; CLINDAMYCIN PHOSPHATE PLUS RETINOIC ACID; MICROSPHERE; RETINOIC ACID; ANTIINFECTIVE AGENT; CLINDAMYCIN; DERMATOLOGICAL AGENT; NAPHTHALENE DERIVATIVE;

ACNE; ADULT; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FACE; FEMALE; GEL; HUMAN; MALE; PATIENT ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SKIN EXFOLIATION; ACNE VULGARIS; ADOLESCENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION;

ACNE VULGARIS; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CLINDAMYCIN; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; FEMALE; GELS; HUMANS; MALE; MICROSPHERES; NAPHTHALENES; TRETINOIN; YOUNG ADULT;

EID: 71049132839     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kligman AM, Fulton JE, Jr, Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol. 1969;99(4):469-476.
2. Gollnick H. Current concepts of the pathogenesis of acne: Implications for drug treatment. Drugs. 2003;63(15):1579-1596. (Pubitemid 36976140)
3. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003;49(3 suppl):S200-S210. (Pubitemid 37046534)
4. Feldman S, Careccia RE, Barham KL, Hancox J. Diagnosis and treatment of acne. Am Fam Physician. 2004;69(9):2123-2130.
5. Smolinski KN, Yan AC. Acne update: 2004. Curr Opin Pediatr. 2004;16(4):385-391. (Pubitemid 39006485)
6. Webster GF. Topical tretinoin in acne therapy. J Am Acad Dermatol. 1998;39(2 pt 3):S38-S44. (Pubitemid 28367285)
7. Wolf JE, Jr., Kaplan D, Kraus SJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: A multicenter, randomized, investigator-blinded study. J Am Acad Dermatol. 2003;49(3 suppl):S211-S217. (Pubitemid 37046535)
8. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: A report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(1 Suppl):S1-37.
9. Embil K, Nacht S. The Microsponge Delivery System (MDS): A topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul. 1996;13(5):575-588. (Pubitemid 26283810)
10. Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: A meta-analysis of five randomized trials. Br J Dermatol. 1998;139 Suppl 52:48-56.
11. Nyirady J, Grossman RM, Nighland M, et al. A comparative trial of two retinoids commonly used in the treatment of acne vulgaris. J Dermatolog Treat. 2001;12(3):149-157. (Pubitemid 33116877)
12. Galvin SA, Gilbert R, Baker M, et al. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol. 1998;139(suppl 52):34-40.
13. Mills OH, Jr., Berger RS. Irritation potential of a new topical tretinoin formulation and a commercially-available tretinoin formulation as measured by patch testing in human subjects. J Am Acad Dermatol. 1998;38(4):S11-16. (Pubitemid 28182951)
14. Lucky AW, Cullen SI, Jarratt MT, Quigley JW. Comparative efficacy and safety of two 0.025% tretinoin gels: Results from a multicenter double-blind, parallel study. J Am Acad Dermatol. 1998;38(4):S17-23. (Pubitemid 28182952)
15. Lucky AW, Cullen SI, Funicella T, et al. Double-blind, vehicle-controlled, multicenter comparison of two 0.025% tretinoin creams in patients with acne vulgaris. J Am Acad Dermatol. 1998;38(4):S24-30. (Pubitemid 28182953)
16. Leyden J, Grove G, Zerweck C. Facial tolerability of topical retinoid therapy. J Drugs Dermatol. 2004;3(6):641-651.
17. Plott RT. Unique aqueous gel formulation results in reduced risk of tretinoin-induced irritation bioassay. J Am Acad Dermatol. 2007;26(2 suppl 2):AB21.
18. Munro V. Statistical Methods for Health Care Research. Philadelphia: J.B. Lippincott Company; 2005.
19. Schlessinger J, Menter A, Gold M, et al. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6(6):607-615.
20. Kircik L, Peredo M, Bucko A, et al. Safety of a novel gel formulation of tretinoin 0.025% and clindamycin phosphate 1.2%: Results from a 52-week open-label study. In press.
21. Leyden J, Wortzman M. A novel gel formulation of clindamycin phosphate/ tretinoin is not associated with acne flaring. Cutis. In press.